Intractable & Rare Diseases Research
Online ISSN : 2186-361X
Print ISSN : 2186-3644
ISSN-L : 2186-3644
Commentary
Therapeutic strategies for Leber's hereditary optic neuropathy: A current update
Nuri GuevenDharmesh Faldu
Author information
JOURNAL FREE ACCESS

2013 Volume 2 Issue 4 Pages 130-135

Details
Abstract

Leber's hereditary optic neuropathy (LHON) is a rare mitochondrial retinopathy, caused by mutations in subunits of complex I of the respiratory chain, which leads to elevated levels of oxidative stress and an insufficient energy supply. This molecular pathology is thought to be responsible for the dysfunction and eventual apoptotic loss of retinal ganglion cells in the eye, which ultimately results in blindness. Many strategies, ranging from neuroprotectants, antioxidants, anti-apoptotic- and anti-inflammatory compounds have been tested with mixed results. Currently, the most promising compounds are shortchain quinones that have been shown to protect the vision of LHON patients during the early stages of the disease. This commentary gives a brief overview on the current status of tested therapeutics and also addresses future developments such as the use of gene therapy that hopefully will provide safe and efficient therapy options for all LHON patients.

Information related to the author
© 2013 International Research and Cooperation Association for Bio & Socio-Sciences Advancement
Previous article Next article
feedback
Top